Chemical Structure (Duloxetine 01)
Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 71335-0509
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-0509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Duloxetine 02)
The graph shows the proportion of patients experiencing relapse over time for two treatments: placebo and duloxetine delayed-release. The x-axis represents the time from randomization to relapse in days, while the y-axis represents the proportion of patients with relapse.*
Figure 2 (Duloxetine 03)
The graph illustrates the proportion of patients who experienced relapse over time after taking either a placebo or Duloxetine delayed-release capsules. It shows that patients who were treated with Duloxetine had a lower rate of relapse compared to the placebo group. This graph can be useful for healthcare professionals when determining the efficacy of the medication in preventing relapses in patients.*
Figure 3 (Duloxetine 04)
Figure 4 (Duloxetine 05)
Figure 5 (Duloxetine 06)
The text provided only includes a table with no clear information on the context or purpose of the data. Therefore, a useful description cannot be generated.*
Figure 6 (Duloxetine 07)
Figure 8 (Duloxetine 08)
This is a chart showing the percentage of patients improved in pain from baseline. The X-axis shows the percent improvement in pain from baseline (BOCF) ranging from 0 to 100. The Y-axis shows the percentage of patients who showed improvement, ranging from 50 to 80 for DUL (duloxetine) 60/120 mg once daily, and 70 for placebo.*
Figure 9 (Duloxetine 09)
This is a chart showing the percentage of patients who improved after taking either a placebo or DUL, with 10 different measurement points ranging from 0 to 100. The text doesn't provide any details on what DUL is or what kind of pain it treats, but it appears to be a pain medication of some sort that was tested against a placebo. The chart also includes a separate graph showing the percent improvement in pain from baseline using the BOCF method.*
Figure 10 (Duloxetine 10)
Label (Lbl713350509)
This appears to be a package information for a generic medication named "Cymbalta 60mg Capsule" packaged by "Bryant Ranck Prepack". The package contains 30 capsules, and the NDC code is 7133505091. The manufacturer of the medication is "Dose Innova, S.L." The expiration date is specified as "MM/YY" format. There are storage instructions provided, and a cautionary note to keep the drugs out of the reach of children. The last line of the text is not related to the medication information and is not readable.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
